Full Text View
Tabular View
Study Results
Related Studies
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
This study has been completed.
Study NCT00466687   Information provided by Vanderbilt-Ingram Cancer Center

First Received on April 25, 2007.   Last Updated on January 23, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
bevacizumab
erlotinib hydrochloride
fluorescence in situ hybridization
gene expression analysis
immunologic technique
laboratory biomarker analysis
biopsy
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services